Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Neurosurg Psychiatry

Retrieve available abstracts of 98 articles:
HTML format



Single Articles


    July 2021
  1. MARGONI M, Villani U, Finos L, Franciotta S, et al
    Neurite orientation dispersion and density imaging discloses early changes in the normal-appearing white matter in paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jul 16. pii: jnnp-2021-326355.
    PubMed    


    June 2021
  2. WANG C, Barton J, Kyle K, Ly L, et al
    Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
    J Neurol Neurosurg Psychiatry. 2021 Jun 29. pii: jnnp-2021-326164.
    PubMed     Abstract available


    May 2021
  3. HEDSTROM AK, Hillert J, Olsson T, Alfredsson L, et al
    Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 May 13. pii: jnnp-2020-325688.
    PubMed     Abstract available


    April 2021
  4. COLATO E, Stutters J, Tur C, Narayanan S, et al
    Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.
    J Neurol Neurosurg Psychiatry. 2021 Apr 20. pii: jnnp-2020-325610.
    PubMed     Abstract available


    March 2021
  5. HAIDER L, Chung K, Birch G, Eshaghi A, et al
    Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up.
    J Neurol Neurosurg Psychiatry. 2021 Mar 30. pii: jnnp-2020-325421.
    PubMed     Abstract available


  6. PFEUFFER S, Ruck T, Pul R, Rolfes L, et al
    Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
    J Neurol Neurosurg Psychiatry. 2021 Mar 12. pii: jnnp-2020-325304.
    PubMed     Abstract available


  7. HEDSTROM AK, Hillert J, Brenner N, Butt J, et al
    DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325676.
    PubMed     Abstract available


  8. MURPHY OC, Mukharesh L, Salazar-Camelo A, Pardo CA, et al
    Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325274.
    PubMed     Abstract available


    February 2021
  9. KOCH-HENRIKSEN N
    It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease.
    J Neurol Neurosurg Psychiatry. 2021 Feb 9. pii: jnnp-2020-325684.
    PubMed    


    January 2021
  10. BURON MD, Kalincik T, Sellebjerg F, Sorensen PS, et al
    Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324869.
    PubMed     Abstract available


  11. PREZIOSA P, Bouman PM, Kiljan S, Steenwijk MD, et al
    Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324391.
    PubMed    


    November 2020
  12. WIJBURG MT, Warnke C, McGuigan C, Koralnik IJ, et al
    Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications.
    J Neurol Neurosurg Psychiatry. 2020 Nov 23. pii: jnnp-2020-324534.
    PubMed     Abstract available


  13. CUNNIFFE N, Vuong KA, Ainslie D, Baker D, et al
    Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Nov 12. pii: jnnp-2020-324286.
    PubMed     Abstract available


  14. KEIR LHM, Breen DP
    REM sleep behaviour disorder in patients without synucleinopathy.
    J Neurol Neurosurg Psychiatry. 2020;91:1239-1240.
    PubMed    


    October 2020
  15. ZHUKOVSKY C, Sandgren S, Silfverberg T, Einarsdottir S, et al
    Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
    J Neurol Neurosurg Psychiatry. 2020 Oct 26. pii: jnnp-2020-323992.
    PubMed     Abstract available


  16. ANNUNZIATA P
    More time, more safety: is this the future optimal way for natalizumab treatment in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2020 Oct 21. pii: jnnp-2020-324032.
    PubMed    


  17. CHISARI CG, Grimaldi LM, Salemi G, Ragonese P, et al
    Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 14. pii: jnnp-2020-323472.
    PubMed     Abstract available


    August 2020
  18. EVANGELOU N, Garjani A, dasNair R, Hunter R, et al
    Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
    J Neurol Neurosurg Psychiatry. 2020 Aug 27. pii: jnnp-2020-324449.
    PubMed    


    July 2020
  19. COMPSTON A
    Review: Multiple sclerosis in the digital age: 'seeing through a glass darkly'.
    J Neurol Neurosurg Psychiatry. 2020 Jul 24. pii: jnnp-2020-323235.
    PubMed    


  20. CHISARI CG, Solaro C, Annunziata P, Bergamaschi R, et al
    Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
    J Neurol Neurosurg Psychiatry. 2020 Jul 13. pii: jnnp-2019-322480.
    PubMed     Abstract available


    June 2020
  21. BUTZKUEVEN H, Kappos L, Wiendl H, Trojano M, et al
    Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    J Neurol Neurosurg Psychiatry. 2020;91:660-668.
    PubMed     Abstract available


    May 2020
  22. ABRAHAMYAN S, Eberspacher B, Hoshi MM, Aly L, et al
    Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 May 5. pii: jnnp-2020-322941.
    PubMed     Abstract available


  23. PREZIOSA P, Rocca MA, Pagani E, Storelli L, et al
    Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    J Neurol Neurosurg Psychiatry. 2020;91:493-502.
    PubMed     Abstract available


    April 2020
  24. CHATAWAY J
    Distribution of plaques in the cerebrum in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Apr 20. pii: jnnp-2019-322431.
    PubMed    


    March 2020
  25. ARNOLD DL, Banwell B, Bar-Or A, Ghezzi A, et al
    Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study.
    J Neurol Neurosurg Psychiatry. 2020 Mar 4. pii: jnnp-2019-322138.
    PubMed     Abstract available


  26. ESHAGHI A
    First approved treatment in children with multiple sclerosis slows brain atrophy.
    J Neurol Neurosurg Psychiatry. 2020 Mar 4. pii: jnnp-2019-322519.
    PubMed    


    February 2020
  27. GERALDES R, Jurynczyk M, Dos Passos G, Prichler A, et al
    Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Feb 7. pii: jnnp-2019-322369.
    PubMed     Abstract available


  28. LIU J, Mori M, Sugimoto K, Uzawa A, et al
    Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS.
    J Neurol Neurosurg Psychiatry. 2020;91:132-139.
    PubMed     Abstract available


    January 2020
  29. PROSPERINI L, Mancinelli C, Haggiag S, Cordioli C, et al
    Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Jan 23. pii: jnnp-2019-322348.
    PubMed     Abstract available


  30. SIMPSON S JR
    Keeping people with MS in the workforce through effective treatment.
    J Neurol Neurosurg Psychiatry. 2020;91:6.
    PubMed    


  31. ROMAN S
    Using clinically stable disease (NEDA 2) as a proxy for disease impact and employment in MS paints an incomplete picture.
    J Neurol Neurosurg Psychiatry. 2020;91:5.
    PubMed    


    November 2019
  32. CHALMER TA, Buron M, Illes Z, Papp V, et al
    Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Nov 14. pii: jnnp-2019-321523.
    PubMed     Abstract available


    August 2019
  33. DEIVA K, Huppke P, Banwell B, Chitnis T, et al
    Consistent control of disease activity with fingolimod versus IFN beta-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS.
    J Neurol Neurosurg Psychiatry. 2019 Aug 29. pii: jnnp-2019-321124.
    PubMed     Abstract available


    July 2019
  34. COCCO E
    Getting older, getting worse: menopause as a turning-point for women living with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jul 17. pii: jnnp-2019-321121.
    PubMed    


    June 2019
  35. SIMPSON S JR, Wang W, Otahal P, Blizzard L, et al
    Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis.
    J Neurol Neurosurg Psychiatry. 2019 Jun 19. pii: jnnp-2018-320189.
    PubMed     Abstract available


  36. SIMPSON R, Simpson S, Ramparsad N, Lawrence M, et al
    Mindfulness-based interventions for mental well-being among people with multiple sclerosis: a systematic review and meta-analysis of randomised controlled trials.
    J Neurol Neurosurg Psychiatry. 2019 Jun 13. pii: jnnp-2018-320165.
    PubMed     Abstract available


  37. BARONCINI D, Annovazzi PO, De Rossi N, Mallucci G, et al
    Impact of natural menopause on multiple sclerosis: a multicentre study.
    J Neurol Neurosurg Psychiatry. 2019 Jun 12. pii: jnnp-2019-320587.
    PubMed     Abstract available


    May 2019
  38. MARTIN SJ, McGlasson S, Hunt D, Overell J, et al
    Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    J Neurol Neurosurg Psychiatry. 2019 May 23. pii: jnnp-2018-319190.
    PubMed     Abstract available


  39. JOHN N, Carroll A, Brownlee WJ, Chataway J, et al
    Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 May 11. pii: jnnp-2019-320687.
    PubMed    


  40. TALLANTYRE EC, Major PC, Atherton MJ, Davies WA, et al
    How common is truly benign MS in a UK population?
    J Neurol Neurosurg Psychiatry. 2019;90:522-528.
    PubMed     Abstract available


    April 2019
  41. BROWNLEE WJ, Solanky B, Prados F, Yiannakas M, et al
    Cortical grey matter sodium accumulation is associated with disability and secondary progressive disease course in relapse-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Apr 4. pii: jnnp-2018-319634.
    PubMed     Abstract available


    March 2019
  42. RAGONESE P
    Food of the gods for the treatment of multiple sclerosis related fatigue?
    J Neurol Neurosurg Psychiatry. 2019 Mar 4. pii: jnnp-2018-319926.
    PubMed    


  43. COE S, Cossington J, Collett J, Soundy A, et al
    A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Mar 4. pii: jnnp-2018-319496.
    PubMed     Abstract available


  44. CRIELAARD L, Kavaliunas A, Ramanujam R, Olsson T, et al
    Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2019 Mar 1. pii: jnnp-2018-319913.
    PubMed     Abstract available


  45. GIOVANNONI G
    The unintended consequences of NICE.
    J Neurol Neurosurg Psychiatry. 2019;90:247-248.
    PubMed    


  46. SCARPAZZA C, Signori A, Prosperini L, Sormani MP, et al
    Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.
    J Neurol Neurosurg Psychiatry. 2019;90:261-267.
    PubMed     Abstract available


    February 2019
  47. ZHANG Y, Zhou Y, van der Mei IAF, Simpson S, et al
    Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Feb 19. pii: jnnp-2018-319870.
    PubMed     Abstract available


    January 2019
  48. MANJALY ZM, Harrison NA, Critchley HD, Do CT, et al
    Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 25. pii: jnnp-2018-320050.
    PubMed     Abstract available


  49. KALINCIK T, Kubala Havrdova E, Horakova D, Izquierdo G, et al
    Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 13. pii: jnnp-2018-319831.
    PubMed     Abstract available


  50. FAREZ MF
    Food allergies and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 10. pii: jnnp-2018-319585.
    PubMed    


  51. ATKINS HL
    Another brick in the wall: further evidence supporting the role of haematopoietic stem cell transplantation in treating multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 10. pii: jnnp-2018-319715.
    PubMed    


  52. SORMANI MP, De Stefano N, Giovannoni G, Langdon D, et al
    Learning ability correlates with brain atrophy and disability progression in RRMS.
    J Neurol Neurosurg Psychiatry. 2019;90:38-43.
    PubMed     Abstract available


  53. WIJBURG MT, Warnke C, Barkhof F, Uitdehaag BMJ, et al
    Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    J Neurol Neurosurg Psychiatry. 2019;90:44-46.
    PubMed     Abstract available


    December 2018
  54. FAKIH R, Diaz-Cruz C, Chua AS, Gonzalez C, et al
    Food allergies are associated with increased disease activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Dec 18. pii: jnnp-2018-319301.
    PubMed     Abstract available


  55. MOORE JJ, Massey JC, Ford CD, Khoo ML, et al
    Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Dec 11. pii: jnnp-2018-319446.
    PubMed     Abstract available


    November 2018
  56. CHARALAMBOUS T, Tur C, Prados F, Kanber B, et al
    Structural network disruption markers explain disability in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Nov 22. pii: jnnp-2018-318440.
    PubMed     Abstract available


    October 2018
  57. OCHI H
    Novel prognostic predictor of brain atrophy in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Oct 15. pii: jnnp-2018-319376.
    PubMed    


    September 2018
  58. PALACE J, Duddy M, Lawton M, Bregenzer T, et al
    Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
    J Neurol Neurosurg Psychiatry. 2018 Sep 21. pii: jnnp-2018-318360.
    PubMed     Abstract available


  59. KOUTSIS G, Breza M, Velonakis G, Tzartos J, et al
    X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association.
    J Neurol Neurosurg Psychiatry. 2018 Sep 8. pii: jnnp-2018-319014.
    PubMed     Abstract available


    July 2018
  60. JACOBS BM, Ammoscato F, Giovannoni G, Baker D, et al
    Cladribine: mechanisms and mysteries in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 10. pii: jnnp-2017-317411.
    PubMed     Abstract available


  61. LANDI D, Ragonese P, Prosperini L, Nociti V, et al
    Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 3. pii: jnnp-2018-318468.
    PubMed     Abstract available


    June 2018
  62. CHEN J, Taylor BV, Blizzard L, Simpson S Jr, et al
    Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    J Neurol Neurosurg Psychiatry. 2018 Jun 19. pii: jnnp-2018-318228.
    PubMed     Abstract available


    May 2018
  63. TAYLOR BV
    Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?
    J Neurol Neurosurg Psychiatry. 2018 May 15. pii: jnnp-2018-318326.
    PubMed    


  64. RATHBONE E, Durant L, Kinsella J, Parker AR, et al
    Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 May 9. pii: jnnp-2018-317947.
    PubMed     Abstract available


    April 2018
  65. CERQUEIRA JJ, Compston DAS, Geraldes R, Rosa MM, et al
    Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2018 Apr 4. pii: jnnp-2017-317509.
    PubMed    


    March 2018
  66. WIJNANDS JMA, Zhu F, Kingwell E, Fisk JD, et al
    Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    J Neurol Neurosurg Psychiatry. 2018 Mar 30. pii: jnnp-2017-317493.
    PubMed     Abstract available


  67. POTTGEN J, Moss-Morris R, Wendebourg JM, Feddersen L, et al
    Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Mar 16. pii: jnnp-2017-317463.
    PubMed     Abstract available


    December 2017
  68. PATTI F
    Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Dec 23. pii: jnnp-2017-317380.
    PubMed    


  69. STURNER KH, Stellmann JP, Dorr J, Paul F, et al
    A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).
    J Neurol Neurosurg Psychiatry. 2017 Dec 16. pii: jnnp-2017-317101.
    PubMed     Abstract available


  70. COCOZZA S, Petracca M, Mormina E, Buyukturkoglu K, et al
    Cerebellar lobule atrophy and disability in progressive MS.
    J Neurol Neurosurg Psychiatry. 2017;88:1065-1072.
    PubMed     Abstract available


    October 2017
  71. AZARY S, Schreiner T, Graves J, Waldman A, et al
    Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-315936.
    PubMed     Abstract available


  72. FITZGERALD K
    Diet and disease modification in multiple sclerosis: a nutritional epidemiology perspective.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-316375.
    PubMed    


  73. MEIJER KA, Eijlers AJC, Geurts JJG, Schoonheim MM, et al
    Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 6. pii: jnnp-2017-316329.
    PubMed     Abstract available


    September 2017
  74. GAJOFATTO A, Nourbakhsh B, Benedetti MD, Waubant E, et al
    Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Sep 22. pii: jnnp-2017-316911.
    PubMed    


  75. PATERGNANI S, Castellazzi M, Bonora M, Marchi S, et al
    Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals.
    J Neurol Neurosurg Psychiatry. 2017 Sep 2. pii: jnnp-2017-316234.
    PubMed    


    August 2017
  76. SPENCER JI, Bell JS, DeLuca GC
    Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier.
    J Neurol Neurosurg Psychiatry. 2017 Aug 31. pii: jnnp-2017-316011.
    PubMed     Abstract available


  77. CALABRESE M, Pitteri M, Farina G, Bajrami A, et al
    Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    J Neurol Neurosurg Psychiatry. 2017 Aug 26. pii: jnnp-2017-316236.
    PubMed     Abstract available


  78. CLAFLIN SB, van der Mei IAF, Taylor BV
    Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016.
    J Neurol Neurosurg Psychiatry. 2017 Aug 2. pii: jnnp-2016-314490.
    PubMed     Abstract available


  79. KOCH-HENRIKSEN N, Laursen B, Stenager E, Magyari M, et al
    Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.
    J Neurol Neurosurg Psychiatry. 2017;88:626-631.
    PubMed     Abstract available


  80. GRYTTEN N
    Survival in multiple sclerosis: things have changed.
    J Neurol Neurosurg Psychiatry. 2017;88:618.
    PubMed    


  81. LASCANO AM, Lalive PH, Hardmeier M, Fuhr P, et al
    Clinical evoked potentials in neurology: a review of techniques and indications.
    J Neurol Neurosurg Psychiatry. 2017;88:688-696.
    PubMed     Abstract available


    July 2017
  82. ZHOU Y, Graves JS, Simpson S Jr, Charlesworth JC, et al
    Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 24. pii: jnnp-2017-315971.
    PubMed     Abstract available


  83. PREZIOSA P, Rocca MA, Mesaros S, Meani A, et al
    Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.
    J Neurol Neurosurg Psychiatry. 2017 Jul 19. pii: jnnp-2017-315863.
    PubMed    


  84. EISELE P, Szabo K, Alonso A, Ong M, et al
    Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 14. pii: jnnp-2017-316102.
    PubMed    


    May 2017
  85. TETTEY P, Simpson S, Taylor B, Ponsonby AL, et al
    An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event.
    J Neurol Neurosurg Psychiatry. 2017;88:395-401.
    PubMed     Abstract available


    April 2017
  86. RAGONESE P
    Mortality studies for multiple sclerosis: still a useful tool to analyse long-term outcome.
    J Neurol Neurosurg Psychiatry. 2017 Apr 28. pii: jnnp-2017-315591.
    PubMed    


  87. OKADA K, Kobata M, Sennari Y, Iwanaka Y, et al
    Levels of nitric oxide metabolites in cerebrospinal fluid correlate with cognitive impairment in early stage multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Apr 26. pii: jnnp-2017-315585.
    PubMed    


  88. LUNDE HB, Assmus J, Kjell-Morten M, Bo L, et al
    Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.
    J Neurol Neurosurg Psychiatry. 2017 Apr 1. pii: jnnp-2016-315238.
    PubMed     Abstract available


  89. COMI G, De Stefano N, Freedman MS, Barkhof F, et al
    Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
    J Neurol Neurosurg Psychiatry. 2017;88:285-294.
    PubMed     Abstract available


    March 2017
  90. MURPHY R, O'Donoghue S, Counihan T, McDonald C, et al
    Neuropsychiatric syndromes of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Mar 11. pii: jnnp-2016-315367.
    PubMed     Abstract available


  91. ZALEWSKI NL, Morris PP, Weinshenker BG, Lucchinetti CF, et al
    Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2017;88:218-225.
    PubMed     Abstract available


    February 2017
  92. JURYNCZYK M, Tackley G, Kong Y, Geraldes R, et al
    Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    J Neurol Neurosurg Psychiatry. 2017;88:132-136.
    PubMed     Abstract available


    December 2016
  93. ROCCA MA, Filippi M
    Modulation of cortical excitability to normalise brain function and improve cognition in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 30. pii: jnnp-2016-315195.
    PubMed    


  94. HULST HE, Goldschmidt T, Nitsche MA, de Wit SJ, et al
    rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 14. pii: jnnp-2016-314224.
    PubMed     Abstract available


    November 2016
  95. TAO C, Simpson S Jr, van der Mei I, Blizzard L, et al
    Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Nov 3. pii: jnnp-2016-314013.
    PubMed     Abstract available


    October 2016
  96. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Posterior lobules of the cerebellum and information processing speed at various stages of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Oct 27. pii: jnnp-2016-313867.
    PubMed     Abstract available


    September 2016
  97. LIZAK N, Lugaresi A, Alroughani R, Lechner-Scott J, et al
    Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Sep 28. pii: jnnp-2016-313976.
    PubMed     Abstract available


  98. KAWACHI I, Lassmann H
    Neurodegeneration in multiple sclerosis and neuromyelitis optica.
    J Neurol Neurosurg Psychiatry. 2016 Sep 26. pii: jnnp-2016-313300.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: